These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 24584872)
1. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. Kuroda J; Shimura Y; Ohta K; Tanaka H; Shibayama H; Kosugi S; Fuchida S; Kobayashi M; Kaneko H; Uoshima N; Ishii K; Nomura S; Taniwaki M; Takaori-Kondo A; Shimazaki C; Tsudo M; Hino M; Matsumura I; Kanakura Y; Int J Hematol; 2014 Apr; 99(4):441-9. PubMed ID: 24584872 [TBL] [Abstract][Full Text] [Related]
2. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561 [TBL] [Abstract][Full Text] [Related]
4. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J; Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675 [TBL] [Abstract][Full Text] [Related]
5. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386 [TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777 [TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
17. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Song MK; Chung JS; Lee JJ; Lee JH; Song IC; Lee SM; Shin DY; Lee GW; Lee IS Acta Haematol; 2015; 134(1):7-16. PubMed ID: 25832367 [TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272 [TBL] [Abstract][Full Text] [Related]
19. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ; Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986 [TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]